Disease · MONDO_0005138

lung carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lung carcinoma. Diseases, record MONDO_0005138. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005138

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lung carcinoma; Open Targets
Open Targets ID: MONDO_0005138; Open Targets
Other names: carcinoma of lung, carcinoma of the lung; Open Targets
Disease Ontology: DOID:3905; Disease Ontology
NCI Thesaurus: C4878; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 1 of its 4 drugs, from ClinicalTrials.gov; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SARACATINIB	CHEMBL217092	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PLICAMYCIN	CHEMBL1237054	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
CENISERTIB	CHEMBL1967878	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets19

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ABL1	Tyrosine-protein kinase ABL1	1	Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
AURKA	Serine/threonine-protein kinase Aurora	1	Serine/threonine-protein kinase Aurora inhibitor	Phase 1	https://conductscience.org/library/genes/6790	Drugs and targets
AURKB	Serine/threonine-protein kinase Aurora	1	Serine/threonine-protein kinase Aurora inhibitor	Phase 1	https://conductscience.org/library/genes/9212	Drugs and targets
AURKC	Serine/threonine-protein kinase Aurora	1	Serine/threonine-protein kinase Aurora inhibitor	Phase 1	https://conductscience.org/library/genes/6795	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/57804	Drugs and targets

1 to 10 of 19

See all 19 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00528645	AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer	Phase 2	23	2014-02-11	Extensive Stage Small Cell Lung Cancer, Lung Metastases, Malignant Pleural Effusion, Recurrent Small Cell Lung Cancer	SARACATINIB	Its record names the disease	ClinicalTrials.gov
NCT02859415	Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases	Phase 1/2	3	2022-04-05	Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal	PLICAMYCIN	Its record names the disease	ClinicalTrials.gov
NCT01097512	AS703569 and Gemcitabine Combination in Advanced Malignancies	Phase 1	66		Pancreatic Cancer	CENISERTIB, GEMCITABINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	1 of 1	2 of 2	3	NCT02859415	Trial comparisons
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: deaths from any cause	0 of 1	0 of 2	3	NCT02859415	Trial comparisons
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: Number of Participants With a Dose-limiting Toxicity (DLT)	0 of 1	0 of 2	3	NCT02859415	Trial comparisons
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: serious adverse events	0 of 1	2 of 2	3	NCT02859415	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
23539344	RESULT	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005138

GET https://conductscience.org/api/diseases/v1/MONDO_0005138/drugs

API reference For AI assistants